Endoscopic features help to identify the histopathological patterns of colorectal polyps in Cronkhite–Canada syndrome
Journal of Digestive Diseases · 2023
DOI: 10.1111/1751-2980.13197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2023. Verfasst von Qiu Shi Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Colonic Polyps, Intestinal Polyposis, Adenoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Elite Training in the Dongcheng District, Beijing, CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Objectives
Cronkhite–Canada syndrome (CCS) is a rare nonhereditary gastrointestinal hamartomatous polyposis syndrome with a high risk of colorectal cancerogenesis. It is challenging to discriminate adenomas from nonneoplastic colorectal polyps macroscopically. This study aimed to explore the endoscopic features of different histopathological patterns of colorectal polyps in CCS.
Methods
Sixty‐seven lesions from 23 CCS patients were prospectively biopsied or resected during the colonoscopic examination for histopathological analysis. The Fisher's exact test and multivariate logistical analysis were conducted to reveal the predictive endoscopic features of CCS polyps with low‐grade dysplasia (LGD) and adenomas.
Results
There were seven (10.4%) adenomas, 20 (29.9%) CCS‐LGD, and 40 (59.7%) nonneoplastic CCS polyps. Polyps were large (>20 mm) in none of the adenomas, 30.0% of CCS‐LGD polyps, and 2.5% of nonneoplastic CCS polyps ( P < 0.001). The color of the polyps was whitish for 71.4% of adenomas, 10.0% of CCS‐LGD polyps, and 15.0% of nonneoplastic CCS polyps ( P = 0.004). Pedunculated polyps were detected in 42.9% of adenomas, 45.0% of CCS‐LGD polyps, and 5.0% of nonneoplastic CCS polyps ( P < 0.001). The proportions of types IV and V I in the Kudo classification were 42.9%, 95.0%, and 35.0% in adenomatous, CCS‐LGD, and nonneoplastic CCS polyps, respectively ( P = 0.002). The endoscopic activity was in remission for 71.4% of adenomas, 5.0% of CCS‐LGD polyps, and 10.0% of nonneoplastic CCS polyps ( P < 0.001).
Conclusion
Endoscopic features, including the size, color, sessility, Kudo's pit pattern classification of polyps, and endoscopic activity, help identify the histopathological patterns of colorectal polyps in CCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China.
- Department of Pathology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China.
ORCID-Profile: Qiu Shi Xu, Jing Nan Li, Ji Li, Jia Ming Qian
Förderung
- Elite Training in the Dongcheng District, Beijing
- CAMS Innovation Fund for Medical Sciences
- National High Level Hospital Clinical Research Funding
- Undergraduate Innovation Program
Zitieren
APA
Xu, Q. S., You, Y., Liu, S., You, W., Zhang, S. Y., Li, J. N., Yang, A. M., Li, J., & Qian, J. M. (2023). Endoscopic features help to identify the histopathological patterns of colorectal polyps in Cronkhite–Canada syndrome. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13197
Vancouver
Xu QS, You Y, Liu S, You W, Zhang SY, Li JN, et al. Endoscopic features help to identify the histopathological patterns of colorectal polyps in Cronkhite–Canada syndrome. Journal of Digestive Diseases. 2023. doi:10.1111/1751-2980.13197
BibTeX
@article{Xu2023,
author = {Xu, Qiu Shi and You, Yan and Liu, Shuang and You, Wen and Zhang, Sheng Yu and Li, Jing Nan and Yang, Ai Ming and Li, Ji and Qian, Jia Ming},
title = {Endoscopic features help to identify the histopathological patterns of colorectal polyps in Cronkhite–Canada syndrome},
journal = {Journal of Digestive Diseases},
year = {2023},
doi = {10.1111/1751-2980.13197}
}
EUVIMED